Asheville’s Avadim Technologies welcomes Dr. Joseph F. Renzulli, II as Chief Medical Officer

From Avadim Technologies, Inc.:

Joseph F. Renzulli, II M.D., FACS, Joins Avadim Technologies as Chief Medical Officer

ASHEVILLE, NC — (Marketwired – January 31, 2017) — Avadim Technologies Inc. (“Avadim”), a true “patient first” life sciences company, is pleased to announce the engagement of Joseph F. Renzulli, II M.D., FACS, as Chief Medical Officer (“CMO”) of the company

Dr. Renzulli is Associate Professor of Urology at The Warren Alpert School of Medicine of Brown University, where he specializes in Genitourinary Malignancies as a certified robotic surgeon. He is a member of the prestigious Alpha Omega Alpha national medical honor society, and serves on the urology staff at The Miriam Hospital and Rhode Island Hospital. His current research interests include the effects of neoadjuvant therapies prior to prostatectomy for high-risk prostate cancer and the role of microvesicles in prostate cancer. Dr. Renzulli is active in numerous clinical trials, has been published over 60 times in peer-reviewed journals, and has presented at many national and local meetings.

“We are extremely pleased to have Dr. Renzulli take on the role of CMO of the company. Our organization is expanding rapidly, and with the appointment of a CMO we have reached another milestone for our company,” says Steve Woody, CEO of Avadim Technologies. “Dr. Renzulli will oversee our clinical research efforts, which continue to validate our platform technology and therapies. As the research becomes more comprehensive, managing cost uncertainty, the regulatory process, evaluation and risk management is critical. Dr. Renzulli will be pivotal in defining, building, and protecting our market franchise, and his experience will enhance the discovery and development of our therapies – giving us great confidence for the further development of the company.”

“I am very excited to join the Avadim team as its Chief Medical Officer,” Dr. Renzulli says. “This is a critically important time for the company. Many health systems are using Avadim’s unique therapies and protocols and they are showing incredible progress in Hospital Acquired Conditions (HAC) with significant CAUTI, UTI, and CLABSI reductions. The company is building a pipeline of therapies with significant potential, and I’m very excited to be working with this exceptional team to discover, develop, and advance these therapies in the coming years.”

About Max Hunt
Max Hunt grew up in South (New) Jersey and graduated from Warren Wilson College in 2011. History nerd; art geek; connoisseur of swimming holes, hot peppers, and plaid clothing. Follow me @J_MaxHunt

Before you comment

The comments section is here to provide a platform for civil dialogue on the issues we face together as a local community. Xpress is committed to offering this platform for all voices, but when the tone of the discussion gets nasty or strays off topic, we believe many people choose not to participate. Xpress editors are determined to moderate comments to ensure a constructive interchange is maintained. All comments judged not to be in keeping with the spirit of civil discourse will be removed and repeat violators will be banned. See here for our terms of service. Thank you for being part of this effort to promote respectful discussion.

Leave a Reply

To leave a reply you may Login with your Mountain Xpress account, connect socially or enter your name and e-mail. Your e-mail address will not be published. All fields are required.